Inventaire - your friends and communities are your best library

Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.

author

Daan P Geerke

Aaron Schimmer

Sonja Zweegman

published in: Leukemia

date of publication: 2011-09-23

main subject: leukemia

Cites articles 43

Date

Title

Authors

2011-05-23

Novel proteasome inhibitors to overcome bortezomib resistance

Lewis E. Kay, Aaron Schimmer
2011-01-31

Differences in reversion of resistance mutations to wild-type under structured treatment interruption and related increase in replication capacity

Rose Kim
2011-05-31

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3

Frits van Rhee, Bart Barlogie, Sarah Waheed, Elias Anaissie
2010-08-20

Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress

Orhan Aktas, Timour Prozorovski, Ulrike Kuckelkorn, Peter-Michael Kloetzel, Lukasz P Bialy, Antje Voigt, Friederike Schröter
2010-08-01

Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium

Paul S. Gaynon
2010-06-17

Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress

Takashi Ishida
2010-08-30

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma

Paul G. Richardson, Kenneth C. Anderson, Madhavi Bandi, Noopur Raje, Dharminder Chauhan, Bryan T Ciccarelli
2010-05-26

Effect of noncompetitive proteasome inhibition on bortezomib resistance

Hans Adomat, Emma Guns, Lewis E. Kay, Robert A. Batey, Aaron Schimmer, Suzanne Trudel
2010-10-01

Resistance to imatinib: mutations and beyond

Paul La Rosée
2010-04-05

Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial

Athanasios Dimopoulos, Ivan Špička, Kudrat M Abdulkadyrov, Anna Dmoszyńska, Antonio Palumbo, Paul G. Richardson
2010-01-01

Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland
2009-10-07

The 26 S proteasome: from basic mechanisms to drug targeting

Aaron Ciechanover
2009-09-10

Proteasome inhibitors in the treatment of multiple myeloma

Robert Z Orlowski, Jatin J Shah
2009-02-19

Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells

Martijn Verdoes
2009-06-14

A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis.

Michael Basler, Marcus Groettrup
2009-08-11

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome

David R Micklem
2009-05-06

Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line
2008-03-01

Proteasome inhibitors in cancer therapy: lessons from the first decade

Robert Z Orlowski
2008-08-01

Mechanisms of proteasome inhibitor action and resistance in cancer
2008-05-23

Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line
2008-06-18

Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein

Bauke Ylstra
2008-05-01

Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

Pasi A Jänne
2008-06-17

Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line
2008-12-01

Drug resistance caused by reversion mutation
2008-06-01

Proteasome beta subunit pharmacogenomics: gene resequencing and functional genomics

Anthony Batzler, Irene Moon, Michelle Hildebrandt, Brooke L Fridley, Shaji K Kumar
2007-07-01

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.
2007-02-23

20S proteasome and its inhibitors: crystallographic knowledge for drug development
2006-06-01

Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132.

Kenneth C. Anderson, Huib Ovaa
2006-02-28

Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
2006-06-20

Proteasome inhibition as novel treatment strategy in leukaemia
2006-10-05

Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells
2006-03-01

Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome

Hidde Ploegh, Huib Ovaa

Article - wd:Q39469395

Welcome to Inventaire

the library of your friends and communities

learn more